318 results on '"Elisaf, M"'
Search Results
2. Comparative effect of 3 different fix-combination antihypertensive treatments in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
3. Comparative effect of delapril-manidipine treatment versus valsartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
4. Comparative effect of valsartan-amlodipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients
5. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
6. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients
7. Comparative effect of delapril-manidipine treatment versus valsartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients
8. Comparative effect of valsartan-amlodipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
9. Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with valsartan/amlodipine in prediabetic hypertensive patients
10. Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with telmisartan/amlodipine in prediabetic patients
11. Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with valsartan/amlodipine in prediabetic patients
12. Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with telmisartan/amlodipine in prediabetic hypertensive patients
13. Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with manidipine/delapril in prediabetic hypertensive patients
14. Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with delapril/manidipine in prediabetic hypertensive patients
15. Statin-associated muscle symptoms in clinical practice: evidence from a 6-year retrospective study
16. Increased lipoprotein(a) multiplies coronary heart disease risk in patients with familial hypercholesterolemia
17. Residual cardiovascular risk of patients with dyslipidemia receiving multifactorial cardiovascular prevention therapy
18. PCSK9 inhibitors: The breakthrough lipid-lowering treatment at real-life setting. A 3-year regional lipid clinic experience
19. Adverse effects associated with lipid-lowering therapy: Evidence from a 6-year real world study
20. Incidence of cardiovascular disease in patients with dyslipidemia receiving multifactorial cardiovascular prevention therapy
21. Lipoprotein (a): A concealed precursor of increased cardiovascular risk? A real-world regional lipid clinic experience
22. Latest European guidelines for dyslipidemias in the setting of familial hypercholesterolemia: Data from the hellas-fh registry
23. PCSK9 inhibitors: The breakthrough lipid-lowering treatment at real-life setting. A 2-year regional lipid clinic experience
24. Coexistence of cardiovascular risk factors in patients with familial hypercholesterolemia: Data from the HELLAS-FH registry
25. PDB128 A NATIONWIDE, OBSERVATIONAL STUDY ASSESSING ADHERENCE TO THE HELLENIC GUIDELINES FOR FOLLOW-UP, CLINICAL, AND LABORATORY EVALUATIONS, IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: THE GLANCE™ STUDY
26. P5321The association of Lp(a) levels and cardiovascular disease in adult patients with familial hypercholesterolemia: analysis from the HELLAS-FH registry
27. 2980The effect of monoclonal antibodies against PCSK9 on circulating CD34+ progenitor cells interactions with platelets in patients with familial hypercholesterolemia
28. P5324Children with familial hypercholesterolemia: lipid profile, treatment and evaluation of different formulas for calculating low-density lipoprotein cholesterol: an analysis from the HELLAS-FH registry
29. Children With Familial Hypercholesterolemia: Cardiometabolic Profile Data From The Hellas-Fh Registry
30. Distance To Targets Of Low-Density Lipoprotein Cholesterol And Eligibility For Treatment With Pcsk9 Inhibitors In Patients At High Cardiovascular Risk
31. Lipid And Glycemic Profile Of Overweight And Obese Patients
32. Adults With Familial Hydrocholesterolemia: Latest Update On Cardiometabolic Profile From The Hellas-Fh Registry
33. Metabolically Healthy Obesity And Risk Of Incident Diabetes In Patients Treated With Statins
34. Effect Of The Fixed-Dose Combination Of Insulin Degludec And Liraglutide On Serum Lipoprotein Metabolism In Patients With Type 2 Diabetes Mellitus
35. Effect Of Anti-Hyperglycemic Agents On Serum Pcsk9 Levels
36. Glucagon-Like Peptide 1 Receptor Agonists Protect Against Stroke In Patients With Diabetes: A Systematic Review And Meta-Analysis
37. Cardiovascular Disease And Lp(A) Levels In Adult Patients With Familial Hydrocholesterolemia
38. Effect Of Dapagliflozin And Sitagliptin On Serum Lipids And Lipoprotein Subfractions
39. ARTERIAL STIFFNESS, ADHERENCE TO TREATMENT AND COGNITIVE FUNCTION WITH THE USE OF IRBESARTAN IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS
40. Protection against stroke with glucagon‐like peptide 1 receptor agonists: a systematic review and meta‐analysis
41. The impact of Temporal Artery Biopsy for the diagnosis of Giant Cell Arteritis in clinical practice in a tertiary University Hospital
42. Treatment of Nephrotic Hyperlipidemia
43. PDB118 - SYSTEMATIC EDUCATION IN PATIENTS WITH T2DM SIGNIFICANTLY IMPROVES ADHERENCE TO THE TREATMENT. THE ADVICE STUDY
44. Glucagon-like peptide 1 receptor agonists and protection against stroke: a systematic review and meta-analysis
45. Carbohydrate metabolism in patients with familial hypercholesterolemia: Data from the HELLAS-FH registry
46. Non-alcoholic fatty liver disease and its association with incident diabetes in statin-treated individuals
47. Atherogenic dyslipidemia increased the risk of incident diabetes in statin-treated individuals
48. Diagnostic lipid changes in patients with visceral leishmaniasis
49. The achievement of the low-density lipoprotein cholesterol target in subjects with familial hypercholesterolemia: The role of PCSK9 inhibitors
50. Cardiovascular profile and treatment of patients with familial hypercholesterolemia in Greece: Preliminary data from the hellenic registry HELLAS-FH
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.